Early oral anticoagulation is non-inferior to delayed treatment in patients with ischemic stroke and atrial fibrillation
1. Early DOAC therapy within 4 days was non-inferior to delayed therapy for the composite outcome of recurrent ischemic or ...
Tag: rivaroxaban
Apixaban is associated with a lower risk of gastrointestinal bleeding than other direct oral anticoagulants
1. In this population-based cohort study, apixaban was associated with a lower risk of gastrointestinal bleeding (GIB) as compared to ...
Apixaban is superior to rivaroxaban in patients with atrial fibrillation and valvular heart disease
1. In comparison to rivaroxaban, apixaban was associated with a lower rate of bleeding events and embolic events amongst adults ...
Rivaroxaban does not prevent cardiovascular events in rheumatic heart disease patients with atrial fibrillation
1. Rivaroxaban was not associated with a lower rate of cardiovascular events and death compared to vitamin K antagonist treatment ...
#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage
Click to read this study in JAMA Network Open.
![The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg){kind=logo}
TRAPS: Rivaroxaban vs. Warfarin for Secondary Prevention in Antiphospholipid Syndrome [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
ANNEXA-A and ANNEXA-R trials: Andaxanet Alfa for Reversal of Apixaban and Rivaroxaban [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19
1. The primary efficacy outcome of symptomatic and asymptomatic venous thromboembolism was significantly lower in the rivaroxaban group (3.14%) compared ...
Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19
1. The primary efficacy outcome of symptomatic and asymptomatic venous thromboembolism was significantly lower in the rivaroxaban group (3.14%) compared ...
Rivaroxaban associated with significantly increased risk of major ischemic or hemorrhagic events versus apixaban in patients with atrial fibrillation
1. In patients with atrial fibrillation over 65, treatment with rivaroxaban compared to apixaban was associated with a significantly increased ...